Since the clinical response rate of PD-1/PD-L1 therapy in humans varies from slightly above 10% to over 80% in different tumors and clinical studies, there is considerable interest in using the patient tumor microenvironment to predict treatment outcome. Here, CD274 is linked to neoplasm.